NRC FORM 591M PART 1
(10-2011)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Allegan General Hospital 555 Linn Street Allegan, Michigan 49010 REPORT NUMBER(S) 11-001	Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-14003	21-18659-01	November 14, 2011

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☒ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

Non-cited violation(s) were discussed involving the following requirement(s):

☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Geoffrey M. Warren		11/14/11
BRANCH CHIEF	Tamara E. Bloomer		11/17/11

NRC FORM 591M PART 3
(10-2011)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Allegan General Hospital 555 Linn Street Allegan, Michigan 49010 REPORT NUMBER(S) 11-001	Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-14003	21-18659-01	November 14, 2011

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87131	03.01 - 03.08

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02120	3	Philip J. Harterink, M.D., RSO	(269) 673-8424

☑ Main Office Inspection Next Inspection Date: Nov. 2014

☐ Field Office Inspection

☐ Temporary Job Site Inspection

PROGRAM SCOPE

The licensee was a hospital located in Allegan, Michigan, with authorization to use byproduct materials in Sections 35.100, 35.200, and 35.300. Licensed activities were conducted only at the location indicated on the license. The nuclear medicine department was staffed with two full-time nuclear medicine technologists. The technologists typically administered approximately 100 diagnostic doses monthly and 2 iodine-131 hyperthyroid therapy doses annually with the iodine in capsule form. The diagnostic procedures were predominately technetium-99m cardiac, hepatobiliary, and bone imaging, as well as xenon-133 lung scans. The department received unit doses as needed from a licensed nuclear pharmacy or prepared doses from bulk technetium obtained from the nuclear pharmacy. All waste was either held for decay-in-storage (DIS) or returned to the nuclear pharmacy.

Performance Observations

The inspector observed one diagnostic administration of licensed material, including dose preparation and disposal. Licensee personnel demonstrated well counter and survey meter QC, dose calibrator constancy, package receipt surveys and wipes, and daily and weekly contamination surveys, and described kit preparation, a variety of diagnostic procedures, and iodine-131 therapy procedures. The inspector noted no concerns with these activities. The inspector reviewed written directives for iodine-131 hyperthyroidism therapies and noted no issues. Interviews with licensee personnel indicated adequate knowledge of radiation safety concepts and procedures. Review of licensee dosimetry and survey records indicated no concerns with exposures to radiation workers or general public. The inspector performed independent and confirmatory radiation measurements which indicated results consistent with licensee survey records and postings.